Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Fanin

Showing results (141-150 of 153) with videos related to

Pageof 16
Sort By:
Leukemia|June 29, 2007
Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcomeP Corradini, A Dodero, L Farina, et al.
Bone Marrow Transplantation|June 6, 2007
Treatment of refractory chronic GVHD with rituximab: a GITMO studyF Zaja, A Bacigalupo, F Patriarca, et al.
Leukemia|October 7, 2015
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myelomaM Ladetto, S Ferrero, D Drandi, et al.
Leukemia|May 24, 2003
Treatment of elderly patients (> or =60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocolsF Mandelli, R Latagliata, G Avvisati, et al.
Leukemia Research|February 21, 2023
Comparison between azacitidine and decitabine as front-line therapy in elderly acute myeloid leukemia patients not eligible for intensive chemotherapyL Maurillo, A Spagnoli, A Candoni, et al.
The Pharmacogenomics Journal|May 16, 2012
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and IdarubicinI Iacobucci, A Lonetti, A Candoni, et al.
British Journal of Haematology|November 9, 2021
Long-term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for high-risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Party-EBMTG Gutiérrez-García, C Martínez, A Boumendil, et al.
Leukemia|March 2, 2012
Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patientsA Rambaldi, A Bacigalupo, R Fanin, et al.
Leukemia|April 28, 2016
Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working PartyM Sobh, M Michallet, G Gahrton, et al.
Haematologica|June 19, 2001
Unrelated donor marrow transplantation: an update of the experience of the Italian Bone Marrow Group (GITMO)G Dini, R Cancedda, F Locatelli, et al.
Pageof 16

Showing results (141-150 of 153) with videos related to

Sort By:
Pageof 16
Leukemia|June 29, 2007
Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcomeP Corradini, A Dodero, L Farina, et al.
Bone Marrow Transplantation|June 6, 2007
Treatment of refractory chronic GVHD with rituximab: a GITMO studyF Zaja, A Bacigalupo, F Patriarca, et al.
Leukemia|October 7, 2015
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myelomaM Ladetto, S Ferrero, D Drandi, et al.
Leukemia|May 24, 2003
Treatment of elderly patients (> or =60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocolsF Mandelli, R Latagliata, G Avvisati, et al.
Leukemia Research|February 21, 2023
Comparison between azacitidine and decitabine as front-line therapy in elderly acute myeloid leukemia patients not eligible for intensive chemotherapyL Maurillo, A Spagnoli, A Candoni, et al.
The Pharmacogenomics Journal|May 16, 2012
Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and IdarubicinI Iacobucci, A Lonetti, A Candoni, et al.
British Journal of Haematology|November 9, 2021
Long-term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for high-risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Party-EBMTG Gutiérrez-García, C Martínez, A Boumendil, et al.
Leukemia|March 2, 2012
Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patientsA Rambaldi, A Bacigalupo, R Fanin, et al.
Leukemia|April 28, 2016
Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working PartyM Sobh, M Michallet, G Gahrton, et al.
Haematologica|June 19, 2001
Unrelated donor marrow transplantation: an update of the experience of the Italian Bone Marrow Group (GITMO)G Dini, R Cancedda, F Locatelli, et al.
Pageof 16